US2056046A
(en)
|
1933-05-19 |
1936-09-29 |
Rhone Poulenc Sa |
Manufacture of bases derived from benz-dioxane
|
US2375138A
(en)
|
1942-05-01 |
1945-05-01 |
American Cyanamid Co |
Alkamine esters of aryloxymethyl benzoic acid
|
US2629736A
(en)
|
1951-02-24 |
1953-02-24 |
Searle & Co |
Basically substituted n-alkyl derivatives of alpha, beta, beta-triarylpropionamides
|
US2730544A
(en)
|
1952-07-23 |
1956-01-10 |
Sahyun Lab |
Alkylaminoalkyl esters of hydroxycyclohexylbenzoic acid
|
US2750387A
(en)
|
1953-11-25 |
1956-06-12 |
Searle & Co |
Basically substituted derivatives of diarylaminobenzamides
|
DE1211359B
(de)
|
1955-11-29 |
1966-02-24 |
Oreal |
Oxydationsmittelfreies Kaltfaerbemittel fuer menschliches Haar
|
US2928833A
(en)
|
1959-03-03 |
1960-03-15 |
S E Massengill Company |
Theophylline derivatives
|
US3174901A
(en)
|
1963-01-31 |
1965-03-23 |
Jan Marcel Didier Aron Samuel |
Process for the oral treatment of diabetes
|
US3454635A
(en)
|
1965-07-27 |
1969-07-08 |
Hoechst Ag |
Benzenesulfonyl-ureas and process for their manufacture
|
DE1914999A1
(de)
|
1968-04-04 |
1969-11-06 |
Ciba Geigy |
Neue Guanylhydrazone und Verfahren zu ihrer Herstellung
|
ES385302A1
(es)
|
1970-10-22 |
1973-04-16 |
Miquel S A Lab |
Procedimiento para la obtencion de derivados trisubstitui- dos de etilendiamina.
|
DE2205815A1
(de)
|
1972-02-08 |
1973-08-16 |
Hoechst Ag |
Piperazinderivate und verfahren zu ihrer herstellung
|
JPS5512435B2
(es)
|
1972-07-01 |
1980-04-02 |
|
|
US4005208A
(en)
|
1975-05-16 |
1977-01-25 |
Smithkline Corporation |
N-Heterocyclic-9-xanthenylamines
|
US4061753A
(en)
|
1976-02-06 |
1977-12-06 |
Interx Research Corporation |
Treating psoriasis with transient pro-drug forms of xanthine derivatives
|
DE2758025A1
(de)
|
1977-12-24 |
1979-07-12 |
Bayer Ag |
Neue derivate von 3,4,5-trihydroxypiperidin, verfahren zu ihrer herstellung und ihre verwendung
|
NO154918C
(no)
|
1977-08-27 |
1987-01-14 |
Bayer Ag |
Analogifremgangsmaate til fremstilling av terapeutisk aktive derivater av 3,4,5-trihydroksypiperidin.
|
DE2929596A1
(de)
|
1979-07-21 |
1981-02-05 |
Hoechst Ag |
Verfahren zur herstellung von oxoalkyl-xanthinen
|
GB2084580B
(en)
|
1980-10-01 |
1984-07-04 |
Glaxo Group Ltd |
Aminoalkyl furan derivative
|
US4382091A
(en)
|
1981-04-30 |
1983-05-03 |
Syntex (U.S.A.) Inc. |
Stabilization of 1-substituted imidazole derivatives in talc
|
FR2558162B1
(fr)
|
1984-01-17 |
1986-04-25 |
Adir |
Nouveaux derives de la xanthine, leurs procedes de preparation et les compositions pharmaceutiques les renfermant
|
FI79107C
(fi)
|
1984-06-25 |
1989-11-10 |
Orion Yhtymae Oy |
Foerfarande foer framstaellning av stabil -form av prazosinhydroklorid.
|
JPS6130567A
(ja)
|
1984-07-23 |
1986-02-12 |
Shiseido Co Ltd |
尿素の安定化法
|
JPS61124383A
(ja)
|
1984-11-16 |
1986-06-12 |
Unitika Ltd |
固定化線維素溶解活性酵素の安定化法
|
AR240698A1
(es)
|
1985-01-19 |
1990-09-28 |
Takeda Chemical Industries Ltd |
Procedimiento para preparar compuestos de 5-(4-(2-(5-etil-2-piridil)-etoxi)benzil)-2,4-tiazolidindiona y sus sales
|
CA1242699A
(en)
|
1985-02-01 |
1988-10-04 |
Bristol-Myers Company |
Cefbuperazone and derivatives thereof
|
US4741898A
(en)
|
1985-04-01 |
1988-05-03 |
Fisher Scientific Company |
Stabilized stain composition
|
GB8515934D0
(en)
|
1985-06-24 |
1985-07-24 |
Janssen Pharmaceutica Nv |
(4-piperidinomethyl and-hetero)purines
|
US5258380A
(en)
|
1985-06-24 |
1993-11-02 |
Janssen Pharmaceutica N.V. |
(4-piperidinylmethyl and -hetero)purines
|
EP0223403B1
(en)
|
1985-10-25 |
1993-08-04 |
Beecham Group Plc |
Piperidine derivative, its preparation, and its use as medicament
|
US5034225A
(en)
|
1985-12-17 |
1991-07-23 |
Genentech Inc. |
Stabilized human tissue plasminogen activator compositions
|
US5433959A
(en)
|
1986-02-13 |
1995-07-18 |
Takeda Chemical Industries, Ltd. |
Stabilized pharmaceutical composition
|
ATE72244T1
(de)
|
1986-03-21 |
1992-02-15 |
Heumann Pharma Gmbh & Co |
Kristalline, wasserfreie sigma -form von 2-(4-(2furoyl-(2-piperazin)-1-yl>-4-amino-6,7- dimethoxychinazolinhydrochlorid und verfahren zu ihrer herstellung.
|
US5120712A
(en)
|
1986-05-05 |
1992-06-09 |
The General Hospital Corporation |
Insulinotropic hormone
|
EP1498425A1
(en)
|
1986-05-05 |
2005-01-19 |
The General Hospital Corporation |
Use of glucagone-like-peptide 1 (GLP-1) derivatives for the preparation of pharmaceutical compositions
|
AU619444B2
(en)
|
1986-06-02 |
1992-01-30 |
Nippon Chemiphar Co. Ltd. |
2-(2-aminobenzylsulfinyl)- benzimidazole derivatives
|
US4968672A
(en)
|
1987-01-02 |
1990-11-06 |
The United States Of America As Represented By The Department Of Health And Human Services |
Adenosine receptor prodrugs
|
US4743450A
(en)
|
1987-02-24 |
1988-05-10 |
Warner-Lambert Company |
Stabilized compositions
|
US5093330A
(en)
|
1987-06-15 |
1992-03-03 |
Ciba-Geigy Corporation |
Staurosporine derivatives substituted at methylamino nitrogen
|
JPS6440433A
(en)
|
1987-08-05 |
1989-02-10 |
Green Cross Corp |
Aqueous liquid composition of thrombin
|
ATE117685T1
(de)
|
1988-05-19 |
1995-02-15 |
Chugai Pharmaceutical Co Ltd |
Chinoloncarbonsäure-derivate.
|
US5329025A
(en)
|
1988-09-21 |
1994-07-12 |
G. D. Searle & Co. |
3-azido compound
|
DE3926119A1
(de)
|
1989-08-08 |
1991-02-14 |
Bayer Ag |
3-amino-5-aminocarbonyl-1,2,4-triazol-derivate
|
US5234897A
(en)
|
1989-03-15 |
1993-08-10 |
Bayer Aktiengesellschaft |
Herbicidal 3-amino-5-aminocarbonyl-1,2,4-triazoles
|
GB8906792D0
(en)
|
1989-03-23 |
1989-05-10 |
Beecham Wuelfing Gmbh & Co Kg |
Treatment and compounds
|
DE3916430A1
(de)
|
1989-05-20 |
1990-11-22 |
Bayer Ag |
Verfahren zur herstellung von 3-amino-5-aminocarbonyl-1,2,4-triazol-derivaten
|
US5332744A
(en)
|
1989-05-30 |
1994-07-26 |
Merck & Co., Inc. |
Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists
|
US5223499A
(en)
|
1989-05-30 |
1993-06-29 |
Merck & Co., Inc. |
6-amino substituted imidazo[4,5-bipyridines as angiotensin II antagonists
|
IL94390A
(en)
|
1989-05-30 |
1996-03-31 |
Merck & Co Inc |
The 6-membered trans-nitrogen-containing heterocycles are compressed with imidazo and pharmaceutical preparations containing them
|
FI94339C
(fi)
|
1989-07-21 |
1995-08-25 |
Warner Lambert Co |
Menetelmä farmaseuttisesti käyttökelpoisen /R-(R*,R*)/-2-(4-fluorifenyyli)- , -dihydroksi-5-(1-metyylietyyli)-3-fenyyli-4-/(fenyyliamino)karbonyyli/-1H-pyrroli-1-heptaanihapon ja sen farmaseuttisesti hyväksyttävien suolojen valmistamiseksi
|
HU208115B
(en)
|
1989-10-03 |
1993-08-30 |
Biochemie Gmbh |
New process for producting pleuromutilin derivatives
|
FR2654935B1
(fr)
|
1989-11-28 |
1994-07-01 |
Lvmh Rech |
Utilisation de xanthines, eventuellement incorporees dans des liposomes, pour favoriser la pigmentation de la peau ou des cheveux.
|
DE122007000050I1
(de)
|
1990-02-19 |
2007-11-08 |
Novartis Ag |
Acylverbindungen
|
KR930000861B1
(ko)
|
1990-02-27 |
1993-02-08 |
한미약품공업 주식회사 |
오메프라졸 직장투여 조성물
|
DK0475482T3
(da)
|
1990-09-13 |
1995-04-03 |
Akzo Nobel Nv |
Stabiliserede faste kemiske midler
|
GB9020959D0
(en)
|
1990-09-26 |
1990-11-07 |
Beecham Group Plc |
Novel compounds
|
US5084460A
(en)
|
1990-12-24 |
1992-01-28 |
A. H. Robins Company, Incorporated |
Methods of therapeutic treatment with N-(3-ouinuclidinyl)-2-hydroxybenzamides and thiobenzamides
|
US5602127A
(en)
|
1991-02-06 |
1997-02-11 |
Karl Thomae Gmbh |
(Alkanesultam-1-yl)-benzimidazol-1-yl)-1yl)-methyl-biphenyls useful as angiotensin-II antagonists
|
US5594003A
(en)
|
1991-02-06 |
1997-01-14 |
Dr. Karl Thomae Gmbh |
Tetrahydroimidazo[1,2-a]pyridin-2-yl-(benzimidazol-1-yl)-methyl-biphenyls useful as angiotensin-II antagonists
|
US5614519A
(en)
|
1991-02-06 |
1997-03-25 |
Karl Thomae Gmbh |
(1-(2,3 or 4-N-morpholinoalkyl)-imidazol-4-yl)-benizimidazol-1-yl-methyl]-biphenyls useful as angiotensin-II antagonists
|
GB9109862D0
(en)
|
1991-05-08 |
1991-07-03 |
Beecham Lab Sa |
Pharmaceutical formulations
|
DE4124150A1
(de)
|
1991-07-20 |
1993-01-21 |
Bayer Ag |
Substituierte triazole
|
TW225528B
(es)
|
1992-04-03 |
1994-06-21 |
Ciba Geigy Ag |
|
US5300298A
(en)
|
1992-05-06 |
1994-04-05 |
The Pennsylvania Research Corporation |
Methods of treating obesity with purine related compounds
|
GB9215633D0
(en)
|
1992-07-23 |
1992-09-09 |
Smithkline Beecham Plc |
Novel treatment
|
DE69318077T2
(de)
|
1992-07-31 |
1998-10-29 |
Shionogi & Co |
Triazolylthiomethylthiocephalosporin-Hydrochlorid, sein kristallines Hydrat und seine Herstellung
|
TW252044B
(es)
|
1992-08-10 |
1995-07-21 |
Boehringer Ingelheim Kg |
|
DE4242459A1
(de)
|
1992-12-16 |
1994-06-23 |
Merck Patent Gmbh |
Imidazopyridine
|
EP0638567A4
(en)
|
1993-02-18 |
1995-05-10 |
Kyowa Hakko Kogyo Kk |
ADENOSINE INHIBITORS.
|
JP3726291B2
(ja)
|
1993-07-05 |
2005-12-14 |
三菱ウェルファーマ株式会社 |
安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
|
FR2707641B1
(fr)
|
1993-07-16 |
1995-08-25 |
Fournier Ind & Sante |
Composés de l'imidazol-5-carboxamide, leur procédé de préparation leurs intermédiaires et leur utilisation en thérapeutique.
|
DE4339868A1
(de)
|
1993-11-23 |
1995-05-24 |
Merck Patent Gmbh |
Imidazopyridazine
|
DE4404183A1
(de)
|
1994-02-10 |
1995-08-17 |
Merck Patent Gmbh |
4-Amino-1-piperidylbenzoylguanidine
|
US5545745A
(en)
|
1994-05-23 |
1996-08-13 |
Sepracor, Inc. |
Enantioselective preparation of optically pure albuterol
|
CO4410190A1
(es)
|
1994-09-19 |
1997-01-09 |
Lilly Co Eli |
3-[4-(2-AMINOETOXI)-BENZOIL]-2-ARIL-6-HIDROXIBENZO [b] TIOFENO CRISTALINO
|
ATE248153T1
(de)
|
1994-10-12 |
2003-09-15 |
Euro Celtique Sa |
Neue benzoxazole
|
GB9501178D0
(en)
|
1995-01-20 |
1995-03-08 |
Wellcome Found |
Guanine derivative
|
CA2218548A1
(en)
|
1995-05-19 |
1996-11-21 |
Chiroscience Limited |
Xanthines and their therapeutic use
|
JPH08333339A
(ja)
|
1995-06-08 |
1996-12-17 |
Fujisawa Pharmaceut Co Ltd |
光学活性なピペリジン酢酸誘導体の製造法
|
GB9523752D0
(en)
|
1995-11-21 |
1996-01-24 |
Pfizer Ltd |
Pharmaceutical formulations
|
DE19543478A1
(de)
|
1995-11-22 |
1997-05-28 |
Bayer Ag |
Kristallines Hydrochlorid von {(R)-(-)-2- N-[4-(1,1-Dioxido-3-oxo-2,3-dihydrobenzisothiazol-2-yl)-buytl]-aminomethyl}-chroman
|
FR2742751B1
(fr)
|
1995-12-22 |
1998-01-30 |
Rhone Poulenc Rorer Sa |
Nouveaux taxoides, leur preparation et les compositions pharmaceutiques qui les contiennent
|
CN1209117A
(zh)
|
1995-12-26 |
1999-02-24 |
奥尔顿有限公司 |
N-酰氨基烷基肼亚氨酰胺
|
DE19616486C5
(de)
|
1996-04-25 |
2016-06-30 |
Royalty Pharma Collection Trust |
Verfahren zur Senkung des Blutglukosespiegels in Säugern
|
TWI240627B
(en)
|
1996-04-26 |
2005-10-01 |
Chugai Pharmaceutical Co Ltd |
Erythropoietin solution preparation
|
US5965555A
(en)
|
1996-06-07 |
1999-10-12 |
Hoechst Aktiengesellschaft |
Xanthine compounds having terminally animated alkynol side chains
|
AU1153097A
(en)
|
1996-06-07 |
1998-01-05 |
Eisai Co. Ltd. |
Stable polymorphs of donepezil (1-benzyl-4-{(5,6-dimethoxy-1-indanon)-2-yl}methylpiperidine ) hydrochloride and process for production
|
US5958951A
(en)
|
1996-06-14 |
1999-09-28 |
Novo Nordiskials |
Modified form of the R(-)-N-(4,4-di(3-methylthien-2-yl)but-3-enyl)-nipecotic acid hydrochloride
|
WO2008109681A2
(en)
|
2007-03-08 |
2008-09-12 |
Phenomix Corporation |
Methods and intermediates for synthesis of selective dpp-iv inhibitors
|
US5753635A
(en)
|
1996-08-16 |
1998-05-19 |
Berlex Laboratories, Inc. |
Purine derivatives and their use as anti-coagulants
|
CA2266444C
(en)
|
1996-09-23 |
2007-01-09 |
Eli Lilly And Company |
Olanzapine dihydrate d
|
WO1998018770A1
(en)
|
1996-10-28 |
1998-05-07 |
Novo Nordisk A/S |
A process for the preparation of (-)-3,4-trans-diarylchromans
|
UA65549C2
(uk)
|
1996-11-05 |
2004-04-15 |
Елі Ліллі Енд Компані |
Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
|
DE69732572T2
(de)
|
1996-11-12 |
2005-12-29 |
Novo Nordisk A/S |
Verwendung von glp-1 peptiden
|
GB9623859D0
(en)
|
1996-11-15 |
1997-01-08 |
Chiroscience Ltd |
Novel compounds
|
SK284989B6
(sk)
|
1996-12-24 |
2006-04-06 |
Biogen, Inc. |
Kvapalná kompozícia obsahujúca interferón a spôsob stabilizácie interferónu
|
DE19705233A1
(de)
|
1997-02-12 |
1998-08-13 |
Froelich Juergen C |
Verfahren zur Herstellung einer Formulierung enthaltend Arginin
|
CO4950519A1
(es)
|
1997-02-13 |
2000-09-01 |
Novartis Ag |
Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
|
US6011049A
(en)
|
1997-02-19 |
2000-01-04 |
Warner-Lambert Company |
Combinations for diabetes
|
NZ337592A
(en)
|
1997-03-13 |
2001-01-26 |
Hexal Ag |
Stabilization of acid sensitive benzimidazoles with amino/cyclodextrin combinations
|
US5972332A
(en)
|
1997-04-16 |
1999-10-26 |
The Regents Of The University Of Michigan |
Wound treatment with keratinocytes on a solid support enclosed in a porous material
|
PE79099A1
(es)
|
1997-06-13 |
1999-08-24 |
Lilly Co Eli |
Formulaciones de insulina estables
|
US6174548B1
(en)
|
1998-08-28 |
2001-01-16 |
Andrx Pharmaceuticals, Inc. |
Omeprazole formulation
|
MXPA00005506A
(es)
|
1997-12-05 |
2008-09-11 |
Astrazeneca Uk Ltd |
Compuestos novedosos.
|
ID21411A
(id)
|
1997-12-10 |
1999-06-10 |
Takeda Chemical Industries Ltd |
Agen untuk mengobati daya tahan glukosa yang berisiko tinggi rusak
|
JPH11193270A
(ja)
|
1997-12-26 |
1999-07-21 |
Koei Chem Co Ltd |
光学活性1−メチル−3−ピペリジンメタノールの製造方法
|
ATE242775T1
(de)
|
1998-01-05 |
2003-06-15 |
Eisai Co Ltd |
Purinderivate und antagonisten des adenosin-a2- rezeptors, welche zur vorsorge oder heilung von diabetes dienen
|
CA2319195A1
(en)
|
1998-02-02 |
1999-08-05 |
Trustees Of Tufts College |
Method of regulating glucose metabolism, and reagents related thereto
|
EP1066265A1
(en)
|
1998-03-31 |
2001-01-10 |
Nissan Chemical Industries, Ltd. |
Pyridazinone hydrochloride compound and method for producing the same
|
EP0950658A1
(en)
|
1998-04-13 |
1999-10-20 |
Takeda Chemical Industries, Ltd. |
2-Pipirazinone-1-acetic acid dihydrochloride derivative used to inhibit platelet aggregation
|
US6207207B1
(en)
|
1998-05-01 |
2001-03-27 |
Mars, Incorporated |
Coated confectionery having a crispy starch based center and method of preparation
|
DE19823831A1
(de)
|
1998-05-28 |
1999-12-02 |
Probiodrug Ges Fuer Arzneim |
Neue pharmazeutische Verwendung von Isoleucyl Thiazolidid und seinen Salzen
|
DE19828114A1
(de)
|
1998-06-24 |
2000-01-27 |
Probiodrug Ges Fuer Arzneim |
Produgs instabiler Inhibitoren der Dipeptidyl Peptidase IV
|
DE69928110T2
(de)
|
1998-07-15 |
2006-07-27 |
Asahi Kasei Chemicals Corporation |
Trägerhilfstoff
|
CO5150173A1
(es)
|
1998-12-10 |
2002-04-29 |
Novartis Ag |
Compuestos n-(glicilo sustituido)-2-cianopirrolidinas inhibidores de peptidasa de dipeptidilo-iv (dpp-iv) los cuales son efectivos en el tratamiento de condiciones mediadas por la inhibicion de dpp-iv
|
IT1312018B1
(it)
|
1999-03-19 |
2002-04-04 |
Fassi Aldo |
Procedimento migliorato per la produzione di sali non igroscopicidella l(-)-carnitina.
|
US20040152659A1
(en)
|
1999-05-12 |
2004-08-05 |
Fujisawa Pharmaceutical Co. Ltd. |
Method for the treatment of parkinson's disease comprising administering an A1A2a receptor dual antagonist
|
EP1177797A1
(en)
|
1999-05-12 |
2002-02-06 |
Fujisawa Pharmaceutical Co., Ltd. |
Novel use
|
AU5294100A
(en)
|
1999-05-27 |
2000-12-18 |
University Of Virginia Patent Foundation |
Method and compositions for treating the inflammatory response
|
JP4156807B2
(ja)
|
1999-06-01 |
2008-09-24 |
エラン ファーマ インターナショナル,リミティド |
小型ミル及びその方法
|
US6545002B1
(en)
|
1999-06-01 |
2003-04-08 |
University Of Virginia Patent Foundation |
Substituted 8-phenylxanthines useful as antagonists of A2B adenosine receptors
|
UA71976C2
(en)
|
1999-06-21 |
2005-01-17 |
Boehringer Ingelheim Pharma |
Bicyclic heterocycles and a medicament based thereon
|
US6448323B1
(en)
|
1999-07-09 |
2002-09-10 |
Bpsi Holdings, Inc. |
Film coatings and film coating compositions based on polyvinyl alcohol
|
ES2166270B1
(es)
|
1999-07-27 |
2003-04-01 |
Almirall Prodesfarma Sa |
Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
|
US6515117B2
(en)
|
1999-10-12 |
2003-02-04 |
Bristol-Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6586438B2
(en)
|
1999-11-03 |
2003-07-01 |
Bristol-Myers Squibb Co. |
Antidiabetic formulation and method
|
GB9928330D0
(en)
|
1999-11-30 |
2000-01-26 |
Ferring Bv |
Novel antidiabetic agents
|
KR20020063260A
(ko)
|
1999-12-23 |
2002-08-01 |
노파르티스 아게 |
당 대사 장애를 치료하기 위한 혈당강하제의 용도
|
JP2003519698A
(ja)
|
2000-01-07 |
2003-06-24 |
トランスフォーム ファーマスーティカルズ,インコーポレイテッド |
多様な固体形態のハイスループットでの形成、同定および分析
|
US6362172B2
(en)
|
2000-01-20 |
2002-03-26 |
Bristol-Myers Squibb Company |
Water soluble prodrugs of azole compounds
|
DE122008000018I1
(de)
|
2000-01-21 |
2008-08-14 |
Novartis Pharma Ag |
Zusammensetzungen bestehend aus Dipeptidylpeptidase-IV Inhibitoren und Antidiabetica
|
JP4621326B2
(ja)
|
2000-02-01 |
2011-01-26 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
テプレノンの安定化組成物
|
AU782878B2
(en)
|
2000-02-05 |
2005-09-08 |
Vertex Pharmaceuticals Incorporated |
Pyrazole compositions useful as inhibitors of erk
|
WO2001062295A1
(fr)
|
2000-02-24 |
2001-08-30 |
Takeda Chemical Industries, Ltd. |
Medicaments contenant des ingredients actifs combines
|
EP1132389A1
(en)
|
2000-03-06 |
2001-09-12 |
Vernalis Research Limited |
New aza-indolyl derivatives for the treatment of obesity
|
US6395767B2
(en)
|
2000-03-10 |
2002-05-28 |
Bristol-Myers Squibb Company |
Cyclopropyl-fused pyrrolidine-based inhibitors of dipeptidyl peptidase IV and method
|
GB0006133D0
(en)
|
2000-03-14 |
2000-05-03 |
Smithkline Beecham Plc |
Novel pharmaceutical
|
JP2001278812A
(ja)
|
2000-03-27 |
2001-10-10 |
Kyoto Pharmaceutical Industries Ltd |
錠剤用崩壊剤及びこれを用いた錠剤
|
WO2001072290A2
(en)
|
2000-03-31 |
2001-10-04 |
Probiodrug Ag |
Method for the improvement of islet signaling in diabetes mellitus and for its prevention
|
AU4458401A
(en)
|
2000-03-31 |
2001-10-15 |
Kirin Brewery |
Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability
|
JP2001292388A
(ja)
|
2000-04-05 |
2001-10-19 |
Sharp Corp |
再生装置
|
GB0008694D0
(en)
|
2000-04-07 |
2000-05-31 |
Novartis Ag |
Organic compounds
|
EP1295873A4
(en)
|
2000-06-14 |
2004-05-19 |
|
METHODS OF PRODUCING RACEMIC PIPERIDINE DERIVATIVE AND PRODUCING OPTICALLY ACTIVE PIPERIDINE DERIVATIVE
|
GB0014969D0
(en)
|
2000-06-19 |
2000-08-09 |
Smithkline Beecham Plc |
Novel method of treatment
|
US7078397B2
(en)
|
2000-06-19 |
2006-07-18 |
Smithkline Beecham Corporation |
Combinations of dipeptidyl peptidase IV inhibitors and other antidiabetic agents for the treatment of diabetes mellitus
|
US6689353B1
(en)
|
2000-06-28 |
2004-02-10 |
Bayer Pharmaceuticals Corporation |
Stabilized interleukin 2
|
PL360856A1
(en)
|
2000-07-04 |
2004-09-20 |
Novo Nordisk A/S |
Purine-2,6-diones which are inhibitors of the enzyme dipeptidyl peptidase iv (dpp-iv)
|
NZ524618A
(en)
|
2000-08-10 |
2004-08-27 |
Mitsubishi Pharma Corp |
Proline derivatives and use thereof as drugs
|
US6821978B2
(en)
|
2000-09-19 |
2004-11-23 |
Schering Corporation |
Xanthine phosphodiesterase V inhibitors
|
US20060034922A1
(en)
|
2000-11-03 |
2006-02-16 |
Andrx Labs, Llc |
Controlled release metformin compositions
|
EP1354882A1
(en)
|
2000-12-27 |
2003-10-22 |
Kyowa Hakko Kogyo Co., Ltd. |
Dipeptidyl peptidase iv inhibitor
|
FR2819254B1
(fr)
|
2001-01-08 |
2003-04-18 |
Fournier Lab Sa |
Nouveaux composes de la n-(phenylsulfonyl) glycine, leur procede de preparation et leur utilisation pour obtenir des compostions pharmaceutiques
|
DE10109021A1
(de)
|
2001-02-24 |
2002-09-05 |
Boehringer Ingelheim Pharma |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10117803A1
(de)
|
2001-04-10 |
2002-10-24 |
Boehringer Ingelheim Pharma |
Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
SK10802003A3
(sk)
|
2001-02-02 |
2004-05-04 |
Takeda Chemical Industries, Ltd. |
Kondenzovaná heterocyklická zlúčenina, jej použitie a jej farmaceutický prípravok
|
WO2002066015A1
(en)
|
2001-02-16 |
2002-08-29 |
Bristol-Myers Squibb Pharma Company |
Use of polyalkylamine polymers in controlled release devices
|
MEP59808A
(en)
|
2001-02-24 |
2011-05-10 |
Boehringer Ingelheim Pharma |
Xanthine derivative, production and use thereof as a medicament
|
US6936590B2
(en)
|
2001-03-13 |
2005-08-30 |
Bristol Myers Squibb Company |
C-aryl glucoside SGLT2 inhibitors and method
|
US6693094B2
(en)
|
2001-03-22 |
2004-02-17 |
Chrono Rx Llc |
Biguanide and sulfonylurea formulations for the prevention and treatment of insulin resistance and type 2 diabetes mellitus
|
JP2002348279A
(ja)
|
2001-05-25 |
2002-12-04 |
Nippon Kayaku Co Ltd |
光学活性ピリジルケトン誘導体の製造方法並びに光学活性ピリジルケトン誘導体
|
DE10130371A1
(de)
|
2001-06-23 |
2003-01-02 |
Boehringer Ingelheim Pharma |
Neue Arzneimittelkompositionen auf der Basis von Anticholinergika, Corticosteroiden und Betamimetika
|
GB0115517D0
(en)
|
2001-06-25 |
2001-08-15 |
Ferring Bv |
Novel antidiabetic agents
|
ES2291477T3
(es)
|
2001-06-27 |
2008-03-01 |
Smithkline Beecham Corporation |
Fluoropirrolidinas como inhibidores de dipeptidil peptidasa.
|
ES2339813T3
(es)
|
2001-06-27 |
2010-05-25 |
Glaxosmithkline Llc |
Fluoropirrolidinas como inhibidores de dipeptidil peptidasas.
|
JP2005502624A
(ja)
|
2001-07-03 |
2005-01-27 |
ノボ ノルディスク アクティーゼルスカブ |
糖尿病を治療するための、dpp−ivを阻害するプリン誘導体
|
US6869947B2
(en)
|
2001-07-03 |
2005-03-22 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme DPP-IV
|
UA74912C2
(en)
|
2001-07-06 |
2006-02-15 |
Merck & Co Inc |
Beta-aminotetrahydroimidazo-(1,2-a)-pyrazines and tetratriazolo-(4,3-a)-pyrazines as inhibitors of dipeptylpeptidase for the treatment or prevention of diabetes
|
US7638522B2
(en)
|
2001-08-13 |
2009-12-29 |
Janssen Pharmaceutica N.V. |
Salt of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino] benzonitrile
|
WO2003024965A2
(en)
|
2001-09-19 |
2003-03-27 |
Novo Nordisk A/S |
Heterocyclic compounds that are inhibitors of the enzyme dpp-iv
|
JP2005514008A
(ja)
|
2001-09-24 |
2005-05-19 |
オレゴン ヘルス アンド サイエンス ユニバーシティー |
摂食行動を改変する薬剤をスクリーニングするための、弓状核におけるニューロンの評価方法
|
KR100679990B1
(ko)
|
2001-10-15 |
2007-02-08 |
헤모텍 게엠베하 |
재협착증의 방지를 위한 스텐트의 코팅
|
DE10151296A1
(de)
|
2001-10-17 |
2003-04-30 |
Boehringer Ingelheim Pharma |
Keratinozyten verwendbar als biologisch aktive Substanz bei der Behandlung von Wunden
|
US6723340B2
(en)
|
2001-10-25 |
2004-04-20 |
Depomed, Inc. |
Optimal polymer mixtures for gastric retentive tablets
|
US6861440B2
(en)
|
2001-10-26 |
2005-03-01 |
Hoffmann-La Roche Inc. |
DPP IV inhibitors
|
US20030083354A1
(en)
|
2001-10-26 |
2003-05-01 |
Pediamed Pharmaceuticals, Inc. |
Phenylephrine tannate and pyrilamine tannate salts in pharmaceutical compositions
|
CA2363053C
(en)
|
2001-11-09 |
2011-01-25 |
Bernard Charles Sherman |
Clopidogrel bisulfate tablet formulation
|
WO2003045228A2
(en)
|
2001-11-26 |
2003-06-05 |
Trustees Of Tufts College |
Methods for treating autoimmune disorders, and reagents related thereto
|
WO2003053929A1
(fr)
|
2001-12-21 |
2003-07-03 |
Toray Fine Chemicals Co., Ltd. |
Procede de production de derives de cis-piperidine optiquement actifs
|
US6727261B2
(en)
|
2001-12-27 |
2004-04-27 |
Hoffman-La Roche Inc. |
Pyrido[2,1-A]Isoquinoline derivatives
|
EP2386311A1
(en)
|
2001-12-28 |
2011-11-16 |
NRL Pharma, Inc. |
Compositions for improving lipid metabolism
|
WO2003057235A2
(en)
|
2002-01-10 |
2003-07-17 |
Imperial College Innovations Ltd |
Modification of feeding behavior
|
US20070197552A1
(en)
|
2002-01-11 |
2007-08-23 |
Novo Nordisk A/S |
Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
|
EP1496877B1
(en)
|
2002-01-11 |
2008-10-01 |
Novo Nordisk A/S |
Method and composition for treatment of diabetes, hypertension, chronic heart failure and fluid retentive states
|
PT2260833E
(pt)
|
2002-01-16 |
2012-12-26 |
Boehringer Ingelheim Pharma |
Comprimido farmacêutico de duas camadas compreendendo telmisartan e um diurético
|
WO2003061688A1
(fr)
|
2002-01-21 |
2003-07-31 |
Nrl Pharma, Inc. |
Nouveaux analgesiques
|
EP1333033A1
(en)
|
2002-01-30 |
2003-08-06 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
FAP-activated anti-tumor compounds
|
JP2005517690A
(ja)
|
2002-02-01 |
2005-06-16 |
ファイザー・プロダクツ・インク |
固体薬物分散物を含有する即時放出剤形
|
US7610153B2
(en)
|
2002-02-13 |
2009-10-27 |
Virginia Commonwealth University |
Multi-drug titration and evaluation
|
EP1476139B1
(en)
|
2002-02-21 |
2017-05-17 |
Valeant Pharmaceuticals Luxembourg S.à.r.l. |
Controlled release dosage forms
|
US7074798B2
(en)
|
2002-02-25 |
2006-07-11 |
Eisai Co., Ltd |
Xanthine derivative and DPPIV inhibitor
|
HUP0200849A2
(hu)
|
2002-03-06 |
2004-08-30 |
Sanofi-Synthelabo |
N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
|
JP4298212B2
(ja)
|
2002-03-29 |
2009-07-15 |
大日本印刷株式会社 |
塩酸エピナスチン高融点型結晶の製造法
|
JP2003300977A
(ja)
|
2002-04-10 |
2003-10-21 |
Sumitomo Pharmaceut Co Ltd |
キサンチン誘導体
|
US20050113577A1
(en)
|
2002-04-16 |
2005-05-26 |
Karki Shyam B. |
Solid forms of slats with tyrosine kinase activity
|
EP1500403A4
(en)
|
2002-04-26 |
2008-09-17 |
Ajinomoto Kk |
MEANS FOR THE PREVENTION / TREATMENT OF DIABETES
|
WO2003094909A2
(en)
|
2002-05-09 |
2003-11-20 |
Enos Pharmaceuticals, Inc. |
Methods and compositions for the treatment and prevention of intermittent claudication or alzheimer's disease
|
GB0212412D0
(en)
|
2002-05-29 |
2002-07-10 |
Novartis Ag |
Combination of organic compounds
|
CN101538224A
(zh)
|
2002-05-31 |
2009-09-23 |
先灵公司 |
制备黄嘌呤磷酸二酯酶v抑制剂及其前体的方法
|
AU2003241960B2
(en)
|
2002-06-06 |
2009-07-30 |
Eisai R&D Management Co., Ltd. |
Novel fused imidazole derivative
|
ES2199061B1
(es)
|
2002-06-10 |
2005-02-16 |
Laboratorios Vita, S.A. |
Comprimidos bucodispersables y procedimiento para su obtencion.
|
FR2840897B1
(fr)
|
2002-06-14 |
2004-09-10 |
Fournier Lab Sa |
Nouveaux derives d'arylsulfonamides et leur utilisation en therapeutique
|
US20040002615A1
(en)
|
2002-06-28 |
2004-01-01 |
Allen David Robert |
Preparation of chiral amino-nitriles
|
GB0215676D0
(en)
|
2002-07-05 |
2002-08-14 |
Novartis Ag |
Organic compounds
|
US20040023981A1
(en)
|
2002-07-24 |
2004-02-05 |
Yu Ren |
Salt forms with tyrosine kinase activity
|
TW200409746A
(en)
|
2002-07-26 |
2004-06-16 |
Theravance Inc |
Crystalline β2 adrenergic receptor agonist
|
TW200404796A
(en)
|
2002-08-19 |
2004-04-01 |
Ono Pharmaceutical Co |
Nitrogen-containing compound
|
DE10238243A1
(de)
|
2002-08-21 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US7407955B2
(en)
|
2002-08-21 |
2008-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co., Kg |
8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions
|
CN105001222B
(zh)
|
2002-08-21 |
2017-11-07 |
勃林格殷格翰制药两合公司 |
8‑[3‑氨基‑哌啶‑1‑基]‑黄嘌呤化合物,其制备方法及作为药物制剂的用途
|
US7569574B2
(en)
|
2002-08-22 |
2009-08-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Purine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
US7495005B2
(en)
|
2002-08-22 |
2009-02-24 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, their preparation and their use in pharmaceutical compositions
|
DE10238477A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Purinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10238470A1
(de)
|
2002-08-22 |
2004-03-04 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
DE10238723A1
(de)
|
2002-08-23 |
2004-03-11 |
Bayer Ag |
Phenyl-substituierte Pyrazolyprimidine
|
DE10238724A1
(de)
|
2002-08-23 |
2004-03-04 |
Bayer Ag |
Alkyl-substituierte Pyrazolpyrimidine
|
AU2003262059A1
(en)
|
2002-09-11 |
2004-04-30 |
Takeda Pharmaceutical Company Limited |
Sustained release preparation
|
MXPA05002899A
(es)
|
2002-09-16 |
2005-05-27 |
Wyeth Corp |
Formulaciones de liberacion controlada para administracion oral de un agente terapeutico polipeptido y sus metodos de uso.
|
KR100867485B1
(ko)
|
2002-09-26 |
2008-11-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
병용 의약
|
WO2004033455A2
(en)
|
2002-10-08 |
2004-04-22 |
Novo Nordisk A/S |
Hemisuccinate salts of heterocyclic dpp-iv inhibitors
|
AU2003267732A1
(en)
|
2002-10-08 |
2004-05-04 |
Ranbaxy Laboratories Limited |
Gabapentin tablets and methods for their preparation
|
US20040122048A1
(en)
|
2002-10-11 |
2004-06-24 |
Wyeth Holdings Corporation |
Stabilized pharmaceutical composition containing basic excipients
|
US6861526B2
(en)
|
2002-10-16 |
2005-03-01 |
Pfizer Inc. |
Process for the preparation of (S,S)-cis-2-benzhydryl-3-benzylaminoquinuclidine
|
ATE390416T1
(de)
|
2002-10-18 |
2008-04-15 |
Merck & Co Inc |
Heterozyklische beta-aminoverbindungen als inhibitoren des dipeptidylpeptidase zur behandlung bzw. prevention von diabetes
|
JP2004161749A
(ja)
|
2002-10-24 |
2004-06-10 |
Toray Fine Chemicals Co Ltd |
光学活性含窒素化合物の製造方法
|
WO2004048379A1
(ja)
|
2002-11-01 |
2004-06-10 |
Sumitomo Pharmaceuticals Co., Ltd. |
キサンチン化合物
|
BR0315796A
(pt)
|
2002-11-07 |
2005-09-13 |
Merck & Co Inc |
Composto, composição farmacêutica, e, métodos para tratar diabetes, para tratar hiperglicemia, e para tratar obesidade em um mamìfero
|
DE10251927A1
(de)
|
2002-11-08 |
2004-05-19 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7482337B2
(en)
|
2002-11-08 |
2009-01-27 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Xanthine derivatives, the preparation thereof and their use as pharmaceutical compositions
|
DE10254304A1
(de)
|
2002-11-21 |
2004-06-03 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7109192B2
(en)
|
2002-12-03 |
2006-09-19 |
Boehringer Ingelheim Pharma Gmbh & Co Kg |
Substituted imidazo-pyridinones and imidazo-pyridazinones, the preparation thereof and their use as pharmaceutical compositions
|
UY28103A1
(es)
|
2002-12-03 |
2004-06-30 |
Boehringer Ingelheim Pharma |
Nuevas imidazo-piridinonas sustituidas, su preparación y su empleo como medicacmentos
|
US7420079B2
(en)
|
2002-12-09 |
2008-09-02 |
Bristol-Myers Squibb Company |
Methods and compounds for producing dipeptidyl peptidase IV inhibitors and intermediates thereof
|
WO2004052362A1
(en)
|
2002-12-10 |
2004-06-24 |
Novartis Ag |
Combination of an dpp-iv inhibitor and a ppar-alpha compound
|
US20040152720A1
(en)
|
2002-12-20 |
2004-08-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Powdered medicaments containing a tiotropium salt and salmeterol xinafoate
|
DE10351663A1
(de)
|
2002-12-20 |
2004-07-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Pulverförmige Arzneimittel enthaltend ein Tiotropiumsalz und Salmeterolxinafoat
|
ATE424215T1
(de)
|
2003-01-08 |
2009-03-15 |
Novartis Vaccines & Diagnostic |
Stabilisierte wässrige zusammensetzungen mit gewebefaktorinhibitor (tfpi) oder gewebefaktorinhibitor-variante
|
ATE374766T1
(de)
|
2003-01-14 |
2007-10-15 |
Arena Pharm Inc |
1,2,3-trisubstituierte aryl- und heteroarylderivate als modulatoren des metabolismus zur vorbeugung und behandlung von metabolismus-bedingten krankheiten wie diabetes oder hyperglykämie
|
DE10335027A1
(de)
|
2003-07-31 |
2005-02-17 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verwendung von Angiotensin II Rezeptor Antagonisten
|
WO2004067509A1
(ja)
|
2003-01-31 |
2004-08-12 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
ジペプチジルペプチダーゼivを阻害する化合物
|
PE20040950A1
(es)
|
2003-02-14 |
2005-01-01 |
Theravance Inc |
DERIVADOS DE BIFENILO COMO AGONISTAS DE LOS RECEPTORES ADRENERGICOS ß2 Y COMO ANTAGONISTAS DE LOS RECEPTORES MUSCARINICOS
|
JP2004250336A
(ja)
|
2003-02-18 |
2004-09-09 |
Kao Corp |
コーティング錠及び糖衣錠の製造法
|
US7135575B2
(en)
|
2003-03-03 |
2006-11-14 |
Array Biopharma, Inc. |
P38 inhibitors and methods of use thereof
|
US7442387B2
(en)
|
2003-03-06 |
2008-10-28 |
Astellas Pharma Inc. |
Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
|
MXPA05009564A
(es)
|
2003-03-12 |
2005-11-17 |
Univ Arizona |
Sales de bases debiles.
|
WO2004082402A1
(en)
|
2003-03-18 |
2004-09-30 |
Novartis Ag |
Compositions comprising fatty acids and amino acids
|
US20040220186A1
(en)
|
2003-04-30 |
2004-11-04 |
Pfizer Inc. |
PDE9 inhibitors for treating type 2 diabetes,metabolic syndrome, and cardiovascular disease
|
JPWO2004096806A1
(ja)
|
2003-04-30 |
2006-07-13 |
大日本住友製薬株式会社 |
縮合イミダゾール誘導体
|
TW200510277A
(en)
|
2003-05-27 |
2005-03-16 |
Theravance Inc |
Crystalline form of β2-adrenergic receptor agonist
|
AU2003902828A0
(en)
|
2003-06-05 |
2003-06-26 |
Fujisawa Pharmaceutical Co., Ltd. |
Dpp-iv inhibitor
|
DE10327439A1
(de)
|
2003-06-18 |
2005-01-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazopyridazinon- und Imidazopyridonderivate, deren Herstellung und deren Verwendung als Arzneimittel
|
US7566707B2
(en)
|
2003-06-18 |
2009-07-28 |
Boehringer Ingelheim International Gmbh |
Imidazopyridazinone and imidazopyridone derivatives, the preparation thereof and their use as pharmaceutical compositions
|
ES2327740T3
(es)
|
2003-06-20 |
2009-11-03 |
F. Hoffmann-La Roche Ag |
Hexahidropiridoisoquinolinas como inhibidoras de la dpp-iv.
|
AU2004251830B8
(en)
|
2003-06-20 |
2009-11-26 |
F. Hoffmann-La Roche Ag |
Pyrido[2, 1-A]-isoquinoline derivatives as DPP-IV inhibitors
|
JO2625B1
(en)
|
2003-06-24 |
2011-11-01 |
ميرك شارب اند دوم كوربوريشن |
Phosphoric acid salts of dipeptidyl betidase inhibitor 4
|
AR045047A1
(es)
|
2003-07-11 |
2005-10-12 |
Arena Pharm Inc |
Derivados arilo y heteroarilo trisustituidos como moduladores del metabolismo y de la profilaxis y tratamiento de desordenes relacionados con los mismos
|
AU2004257267B2
(en)
|
2003-07-14 |
2009-12-03 |
Arena Pharmaceuticals,Inc |
Fused-aryl and heteroaryl derivatives as modulators of metabolism and the prophylaxis and treatment of disorders related thereto
|
US20050027012A1
(en)
|
2003-07-16 |
2005-02-03 |
Boehringer Ingelheim International Gmbh |
Tablets containing ambroxol
|
PT1558220E
(pt)
|
2003-07-24 |
2010-03-12 |
Rasendrakumar Jha |
Composições orais para tratamento da diabetes
|
US6995183B2
(en)
|
2003-08-01 |
2006-02-07 |
Bristol Myers Squibb Company |
Adamantylglycine-based inhibitors of dipeptidyl peptidase IV and methods
|
KR20060054410A
(ko)
|
2003-08-01 |
2006-05-22 |
제네랩스 테크놀로지스, 인코포레이티드 |
플라비비리다에에 대한 2고리 이미다졸 유도체
|
US20070190022A1
(en)
|
2003-08-29 |
2007-08-16 |
Bacopoulos Nicholas G |
Combination methods of treating cancer
|
EP1699777B1
(en)
|
2003-09-08 |
2012-12-12 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors
|
EP1671649B1
(en)
|
2003-10-03 |
2011-11-23 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase IV inhibitors for treating diabetic patients with sulfonylurea secondary failure
|
BR0304443B1
(pt)
|
2003-10-28 |
2012-08-21 |
|
processo para obtenção de concentrados de titánio com elevado teor de tio2 e baixo teor de radionuclìdeos a partir de concentrados mecánicos de anatásio.
|
US7107714B2
(en)
|
2003-11-10 |
2006-09-19 |
Marketing Displays, Inc. |
Portable snap-fit sign stand
|
CA2545311C
(en)
|
2003-11-12 |
2012-01-03 |
Phenomix Corporation |
Heterocyclic boronic acid compounds
|
KR20120008093A
(ko)
|
2003-11-17 |
2012-01-25 |
노파르티스 아게 |
디펩티딜 펩티다제 ⅳ 억제제의 용도
|
DE10355304A1
(de)
|
2003-11-27 |
2005-06-23 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(Piperazin-1-yl)-und 8-([1,4]Diazepan-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
US20070219178A1
(en)
|
2003-12-04 |
2007-09-20 |
Eisai Co., Ltd. |
Preventive or therapeutic agents for multiple sclerosis
|
US7217711B2
(en)
|
2003-12-17 |
2007-05-15 |
Boehringer Ingelheim International Gmbh |
Piperazin-1-yl and 2-([1,4]diazepan-1-yl)-imidazo[4,5-d]-pyridazin-4-ones, the preparation thereof and their use as pharmaceutical compositions
|
DE10359098A1
(de)
|
2003-12-17 |
2005-07-28 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 2-(Piperazin-1-yl)- und 2-([1,4]Diazepan-1-yl)-imidazo[4,5-d]pyridazin-4-one, deren Herstellung und deren Verwendung als Arzneimittel
|
US7355051B2
(en)
|
2003-12-18 |
2008-04-08 |
Tibotec Pharmaceuticals |
Piperdine-amino-benzimidazole derivatives as inhibitors of respiratory syncytial virus replication
|
DE10360835A1
(de)
|
2003-12-23 |
2005-07-21 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Bicyclische Imidazolverbindungen, deren Herstellung und deren Verwendung als Arzneimittel
|
NZ547965A
(en)
|
2003-12-24 |
2009-12-24 |
Prosidion Ltd |
1,2,4-Oxadiazole derivatives as GPCR receptor agonists
|
LT3366283T
(lt)
|
2004-01-20 |
2021-12-10 |
Novartis Ag |
Tiesioginio presavimo formulė ir procesas
|
WO2005070390A2
(en)
|
2004-01-21 |
2005-08-04 |
Janssen Pharmaceutica N.V. |
Mitratapide oral solution
|
SI1712547T1
(sl)
|
2004-02-05 |
2012-04-30 |
Kyorin Seiyaku Kk |
Bicikloestrski derivat
|
AU2005219508B2
(en)
|
2004-02-18 |
2012-02-16 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthine, the production thereof and the use in the form of a DPP inhibitor
|
US7501426B2
(en)
|
2004-02-18 |
2009-03-10 |
Boehringer Ingelheim International Gmbh |
8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions
|
DE102004019540A1
(de)
|
2004-04-22 |
2005-11-10 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen
|
DE102004009039A1
(de)
|
2004-02-23 |
2005-09-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-[3-Amino-piperidin-1-yl]-xanthine, deren Herstellung und Verwendung als Arzneimittel
|
EP1593671A1
(en)
|
2004-03-05 |
2005-11-09 |
Graffinity Pharmaceuticals AG |
DPP-IV inhibitors
|
US7393847B2
(en)
|
2004-03-13 |
2008-07-01 |
Boehringer Ingleheim International Gmbh |
Imidazopyridazinediones, their preparation and their use as pharmaceutical compositions
|
GEP20094679B
(en)
|
2004-03-15 |
2009-05-10 |
Takeda Pharmaceuticals Co |
Dipeptidyl peptidase inhibitors
|
BRPI0508830B8
(pt)
|
2004-03-16 |
2021-05-25 |
Boehringer Ingelheim Int |
derivados de benzeno substituídos por glucopiranosila, medicamentos contendo esses compostos, seu uso e processo para sua fabricação
|
EP1577306A1
(de)
|
2004-03-17 |
2005-09-21 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
Neue Benzoxazinonderivate als langwirksame Betamimetika zur Behandlung von Atemwegserkrankungen
|
US7179809B2
(en)
|
2004-04-10 |
2007-02-20 |
Boehringer Ingelheim International Gmbh |
2-Amino-imidazo[4,5-d]pyridazin-4-ones, their preparation and their use as pharmaceutical compositions
|
WO2005097798A1
(de)
|
2004-04-10 |
2005-10-20 |
Boehringer Ingelheim International Gmbh |
Neue 2-amino-imidazo[4,5-d]pyridazin-4-one und 2-amino-imidazo[4,5-c]pyridin-4-one, deren herstellung und deren verwendung als arzneimittel
|
US7741082B2
(en)
|
2004-04-14 |
2010-06-22 |
Bristol-Myers Squibb Company |
Process for preparing dipeptidyl peptidase IV inhibitors and intermediates therefor
|
US20050239778A1
(en)
|
2004-04-22 |
2005-10-27 |
Boehringer Ingelheim International Gmbh |
Novel medicament combinations for the treatment of respiratory diseases
|
US20050244502A1
(en)
|
2004-04-28 |
2005-11-03 |
Mathias Neil R |
Composition for enhancing absorption of a drug and method
|
DE102004022970A1
(de)
|
2004-05-10 |
2005-12-01 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazolderivate, deren Herstellung und deren Verwendung als Intermediate zur Herstellung von Arzneimitteln und Pestiziden
|
US7439370B2
(en)
|
2004-05-10 |
2008-10-21 |
Boehringer Ingelheim International Gmbh |
Imidazole derivatives, their preparation and their use as intermediates for the preparation of pharmaceutical compositions and pesticides
|
PL1753748T3
(pl)
|
2004-05-12 |
2010-01-29 |
Pfizer Prod Inc |
Pochodne proliny i ich zastosowanie jako inhibitorów peptydazy dipeptylowej IV
|
DE102004024454A1
(de)
|
2004-05-14 |
2005-12-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Enantiomerenreine Betaagonisten, Verfahren zu deren Herstellung und deren Verwendung als Arzneimittel
|
PE20060315A1
(es)
|
2004-05-24 |
2006-05-15 |
Irm Llc |
Compuestos de tiazol como moduladores de ppar
|
US7214702B2
(en)
|
2004-05-25 |
2007-05-08 |
Bristol-Myers Squibb Company |
Process for producing a dipeptidyl peptidase IV inhibitor
|
TWI354569B
(en)
|
2004-05-28 |
2011-12-21 |
Bristol Myers Squibb Co |
Coated tablet formulation and method
|
CA2567309A1
(en)
|
2004-06-01 |
2005-12-15 |
Ares Trading S.A. |
Method of stabilizing proteins
|
WO2005117861A1
(en)
|
2004-06-04 |
2005-12-15 |
Novartis Ag |
Use of organic compounds
|
EP1753459A2
(en)
|
2004-06-09 |
2007-02-21 |
Yasoo Health |
Composition and method for improving pancreatic islet cell survival
|
DE102004030502A1
(de)
|
2004-06-24 |
2006-01-12 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Imidazole und Triazole, deren Herstellung und Verwendung als Arzneimittel
|
RU2007105346A
(ru)
|
2004-07-14 |
2008-09-27 |
Новартис АГ (CH) |
Комбинация ингибиторов dpp-iv и соединений, модулирующих 5-нт3-и/или 5-нт4-рецепторы
|
JP2006045156A
(ja)
|
2004-08-06 |
2006-02-16 |
Sumitomo Pharmaceut Co Ltd |
縮合ピラゾール誘導体
|
TW200613275A
(en)
|
2004-08-24 |
2006-05-01 |
Recordati Ireland Ltd |
Lercanidipine salts
|
WO2006022428A1
(ja)
|
2004-08-26 |
2006-03-02 |
Takeda Pharmaceutical Company Limited |
糖尿病治療剤
|
DE102004043944A1
(de)
|
2004-09-11 |
2006-03-30 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 8-(3-Amino-piperidin-1-yl)-7-(but-2-inyl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
DE102004044221A1
(de)
|
2004-09-14 |
2006-03-16 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue 3-Methyl-7-butinyl-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
CN1759834B
(zh)
|
2004-09-17 |
2010-06-23 |
中国医学科学院医药生物技术研究所 |
黄连素或其与辛伐他汀联合在制备用于预防或治疗与血脂有关疾病或症状的产品中用途
|
EP1799637A1
(en)
|
2004-09-23 |
2007-06-27 |
Amgen, Inc |
Substituted sulfonamidopropionamides and methods of use
|
JP2008515905A
(ja)
|
2004-10-08 |
2008-05-15 |
ノバルティス アクチエンゲゼルシャフト |
有機化合物の組合せ剤
|
AP2007003973A0
(en)
|
2004-10-12 |
2007-07-30 |
Glenmark Pharmaceuticals Sa |
Novel dideptidyl peptidase IV inhibitors, pharmaceutical compositions containing them, and proces for their preparation
|
CA2581298A1
(en)
|
2004-10-25 |
2006-05-04 |
Novartis Ag |
Combination of dpp-iv inhibitor, ppar antidiabetic and metformin
|
DE102005013967A1
(de)
|
2004-11-05 |
2006-10-05 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Neue Bradykinin-B1-Antagonisten, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
|
DE102004054054A1
(de)
|
2004-11-05 |
2006-05-11 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine
|
JP2006137678A
(ja)
|
2004-11-10 |
2006-06-01 |
Shionogi & Co Ltd |
インターロイキン−2組成物
|
CA2590912A1
(en)
|
2004-12-24 |
2006-06-29 |
Dainippon Sumitomo Pharma Co., Ltd. |
Bicyclic pyrrole derivatives
|
KR100760430B1
(ko)
|
2004-12-31 |
2007-10-04 |
한미약품 주식회사 |
당뇨병 치료제의 경구 투여용 서방성 복합 제제 및 이의제조 방법
|
DOP2006000008A
(es)
|
2005-01-10 |
2006-08-31 |
Arena Pharm Inc |
Terapia combinada para el tratamiento de la diabetes y afecciones relacionadas y para el tratamiento de afecciones que mejoran mediante un incremento de la concentración sanguínea de glp-1
|
MY148521A
(en)
|
2005-01-10 |
2013-04-30 |
Arena Pharm Inc |
Substituted pyridinyl and pyrimidinyl derivatives as modulators of metabolism and the treatment of disorders related thereto
|
GT200600008A
(es)
|
2005-01-18 |
2006-08-09 |
|
Formulacion de compresion directa y proceso
|
US8003790B2
(en)
|
2005-02-18 |
2011-08-23 |
Mitsubishi Tanabe Pharma Corporation |
Salt of proline derivative, solvate thereof, and production method thereof
|
CN101146801A
(zh)
|
2005-03-22 |
2008-03-19 |
霍夫曼-拉罗奇有限公司 |
新型的dpp-iv抑制剂的盐和多晶型物
|
WO2006111169A1
(en)
|
2005-04-21 |
2006-10-26 |
Gastrotech Pharma A/S |
Pharmaceutical preparations of a glp-1 molecule and an anti-emetic drug
|
CN101277949A
(zh)
|
2005-04-22 |
2008-10-01 |
阿兰托斯制药控股公司 |
二肽基肽酶-ⅳ抑制剂
|
CN100539942C
(zh)
|
2005-04-25 |
2009-09-16 |
株式会社日立制作所 |
利用磁共振的检查装置及核磁共振信号接收用线圈
|
EP1882474B1
(en)
|
2005-04-26 |
2010-11-03 |
Mitsubishi Tanabe Pharma Corporation |
Prophylactic/therapeutic agent for abnormalities of lipid metabolism
|
UA91546C2
(uk)
|
2005-05-03 |
2010-08-10 |
Бьорінгер Інгельхайм Інтернаціональ Гмбх |
КРИСТАЛІЧНА ФОРМА 1-ХЛОР-4-(β-D-ГЛЮКОПІРАНОЗ-1-ИЛ)-2-[4-((S)-ТЕТРАГІДРОФУРАН-3-ІЛОКСИ)-БЕНЗИЛ]-БЕНЗОЛУ, СПОСІБ ЇЇ ОДЕРЖАННЯ ТА ЇЇ ЗАСТОСУВАННЯ ПРИ ПРИГОТУВАННІ ЛІКАРСЬКИХ ЗАСОБІВ
|
CA2608311C
(en)
|
2005-05-13 |
2012-11-27 |
Eli Lilly And Company |
Glp-1 pegylated compounds
|
CN101203494A
(zh)
|
2005-05-25 |
2008-06-18 |
惠氏公司 |
合成经取代3-氰基喹啉和其中间物的方法
|
CN101237870B
(zh)
|
2005-06-03 |
2011-05-25 |
田边三菱制药株式会社 |
伴随的药物试剂及其用途
|
MY152185A
(en)
|
2005-06-10 |
2014-08-29 |
Novartis Ag |
Modified release 1-[(3-hydroxy-adamant-1-ylamino)-acetyl]-pyrrolidine-2(s)-carbonitrile formulation
|
GT200600218A
(es)
|
2005-06-10 |
2007-03-28 |
|
Formulación y proceso de compresión directa
|
EA016397B1
(ru)
|
2005-06-20 |
2012-04-30 |
Декоуд Дженетикс Ехф. |
Генетические варианты гена tcf7l2 как диагностические маркеры риска возникновения сахарного диабета ii типа
|
AU2006265975B2
(en)
|
2005-07-01 |
2011-12-15 |
Merck Sharp & Dohme Corp. |
Process for synthesizing a CETP inhibitor
|
ATE483732T1
(de)
|
2005-07-08 |
2010-10-15 |
Pfizer Ltd |
Madcam-antikörper
|
UY29694A1
(es)
|
2005-07-28 |
2007-02-28 |
Boehringer Ingelheim Int |
Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
|
DE102005035891A1
(de)
|
2005-07-30 |
2007-02-08 |
Boehringer Ingelheim Pharma Gmbh & Co. Kg |
8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel
|
EP1912938A2
(en)
|
2005-08-04 |
2008-04-23 |
Novartis AG |
Salts of vildagliptin
|
CN101232873A
(zh)
|
2005-08-11 |
2008-07-30 |
霍夫曼-拉罗奇有限公司 |
含有dpp-iv抑制剂的药物组合物
|
EP1760076A1
(en)
|
2005-09-02 |
2007-03-07 |
Ferring B.V. |
FAP Inhibitors
|
EP2073810B1
(en)
|
2006-09-13 |
2011-08-31 |
Takeda Pharmaceutical Company Limited |
Use of 2-6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2h-pyrimidin-1-ylmethyl-4-fluoro-benzonitrile for treating diabetes, cancer, autoimmune disorders and hiv infection
|
CA2622608C
(en)
|
2005-09-14 |
2014-08-19 |
Takeda Pharmaceutical Company Limited |
Dipeptidyl peptidase inhibitors for treating diabetes
|
MY147393A
(en)
|
2005-09-14 |
2012-11-30 |
Takeda Pharmaceutical |
Administration of dipeptidyl peptidase inhibitors
|
CA2619093A1
(en)
|
2005-09-16 |
2007-03-29 |
Arena Pharmaceuticals, Inc. |
Modulators of metabolism and the treatment of disorders related thereto
|
TW200745079A
(en)
|
2005-09-16 |
2007-12-16 |
Takeda Pharmaceuticals Co |
Polymorphs of benzoate salt of 2-[[6-[(3R)-3-amino-1-piperidinyl]-3,4-dihydro-3-methyl-2,4-dioxo-1(2H)-pyrimidinyl]methyl]-benzonitrile and methods of use therefor
|
CN102675221A
(zh)
|
2005-09-16 |
2012-09-19 |
武田药品工业株式会社 |
用于制备嘧啶二酮衍生物的方法中的中间体
|
JP5072848B2
(ja)
|
2005-09-20 |
2012-11-14 |
ノバルティス アーゲー |
低血糖イベントを低減するためのdpp−iv阻害剤の使用
|
EP1945190A1
(en)
|
2005-09-22 |
2008-07-23 |
Swissco Devcelopment AG |
Effervescent metformin composition and tablets and granules made therefrom
|
JOP20180109A1
(ar)
|
2005-09-29 |
2019-01-30 |
Novartis Ag |
تركيبة جديدة
|
JP2009513633A
(ja)
|
2005-10-25 |
2009-04-02 |
メルク エンド カムパニー インコーポレーテッド |
糖尿病および高血圧を治療するためのジペプチジルペプチダーゼ−4インヒビターと降圧薬との組合せ
|
CN101300298A
(zh)
|
2005-11-04 |
2008-11-05 |
Ls电线有限公司 |
Mdh-聚合物混合粒子的合成
|
WO2007078726A2
(en)
|
2005-12-16 |
2007-07-12 |
Merck & Co., Inc. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
|
ATE482947T1
(de)
|
2005-12-21 |
2010-10-15 |
Hoffmann La Roche |
Neues salz und polymorph des dpp-iv-hemmers
|
EP1966215A1
(en)
|
2005-12-23 |
2008-09-10 |
Novartis AG |
Condensed heterocyclic compounds useful as dpp-iv inhibitors
|
GB0526291D0
(en)
|
2005-12-23 |
2006-02-01 |
Prosidion Ltd |
Therapeutic method
|
JP5094416B2
(ja)
|
2005-12-28 |
2012-12-12 |
武田薬品工業株式会社 |
糖尿病治療剤
|
CA2635399A1
(en)
|
2006-01-06 |
2007-10-25 |
Novartis Ag |
Use.of vildagliptin for the treatment of diabetes
|
JP2009531291A
(ja)
|
2006-02-15 |
2009-09-03 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
グルコピラノシル置換ベンゾニトリル誘導体、それらの化合物を含有する医薬組成物、それらの使用及び製造方法
|
WO2007099345A1
(en)
|
2006-03-02 |
2007-09-07 |
Betagenon Ab |
Medical use of bmp-2 and/ or bmp-4
|
EP1999108A1
(en)
|
2006-03-28 |
2008-12-10 |
Takeda Pharmaceutical Company Limited |
Preparation of (r)-3-aminopiperidine dihydrochloride
|
PE20071221A1
(es)
|
2006-04-11 |
2007-12-14 |
Arena Pharm Inc |
Agonistas del receptor gpr119 en metodos para aumentar la masa osea y para tratar la osteoporosis y otras afecciones caracterizadas por masa osea baja, y la terapia combinada relacionada a estos agonistas
|
US8455435B2
(en)
|
2006-04-19 |
2013-06-04 |
Ludwig-Maximilians-Universitat Munchen |
Remedies for ischemia
|
EP1852108A1
(en)
|
2006-05-04 |
2007-11-07 |
Boehringer Ingelheim Pharma GmbH & Co.KG |
DPP IV inhibitor formulations
|
CA2810839A1
(en)
|
2006-05-04 |
2007-11-15 |
Boehringer Ingelheim International Gmbh |
A polymorphic form of 1-[(4-methyl-quinazolin-2-yl)methyl]-3-methyl-7-(2-butyn-1-yl)-8-(3-(r)-amino-piperidin-1-yl)-xanthine
|
PE20110235A1
(es)
|
2006-05-04 |
2011-04-14 |
Boehringer Ingelheim Int |
Combinaciones farmaceuticas que comprenden linagliptina y metmorfina
|
KR101424832B1
(ko)
|
2006-05-16 |
2014-08-06 |
길리애드 사이언시즈, 인코포레이티드 |
악성 혈액 종양 치료 방법 및 악성 혈액 종양 치료용 조성물
|
KR20070111099A
(ko)
|
2006-05-16 |
2007-11-21 |
영진약품공업주식회사 |
시타글립틴 염산염의 신규 결정형, 이의 제조 방법과 이를포함하는 약학적 조성물
|
US20080064717A1
(en)
|
2006-05-19 |
2008-03-13 |
Rajesh Iyengar |
Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme
|
KR100858848B1
(ko)
|
2006-05-23 |
2008-09-17 |
한올제약주식회사 |
메트포르민 서방정
|
WO2007149797A2
(en)
|
2006-06-19 |
2007-12-27 |
Novartis Ag |
Use of organic compounds
|
WO2007148185A2
(en)
|
2006-06-21 |
2007-12-27 |
Pfizer Products Inc. |
Substituted 3 -amino- pyrrolidino-4 -lactams as dpp inhibitors
|
AT503443B1
(de)
|
2006-06-23 |
2007-10-15 |
Leopold Franzens Uni Innsbruck |
Verfahren zur herstellung einer eisfläche für eissportbahnen
|
EP2035395A2
(en)
|
2006-06-27 |
2009-03-18 |
Glenmark Pharmaceuticals S.A. |
Novel processes for the preparation of dpp iv inhibitors
|
TW200811140A
(en)
|
2006-07-06 |
2008-03-01 |
Arena Pharm Inc |
Modulators of metabolism and the treatment of disorders related thereto
|
TW200811147A
(en)
|
2006-07-06 |
2008-03-01 |
Arena Pharm Inc |
Modulators of metabolism and the treatment of disorders related thereto
|
JP2010500326A
(ja)
|
2006-08-08 |
2010-01-07 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
糖尿病の治療のためのdpp−iv阻害剤としてのピロロ[3,2−d]ピリミジン
|
US8039441B2
(en)
|
2006-08-15 |
2011-10-18 |
Boehringer Ingelheim International Gmbh |
Glucopyranosyl-substituted cyclopropylbenzene derivatives, pharmaceutical compositions containing such compounds, their use as SGLT inhibitors and process for their manufacture
|
NZ574664A
(en)
|
2006-08-17 |
2012-06-29 |
Wellstat Therapeutics Corp |
Combination treatment for metabolic disorders comprising an incretin mimetic such as exendin or a dppv iv inhibitor
|
CL2007002499A1
(es)
|
2006-08-30 |
2008-03-14 |
Phenomix Corp |
Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
|
DE102006042586B4
(de)
|
2006-09-11 |
2014-01-16 |
Betanie B.V. International Trading |
Verfahren zum mikropartikulären Beladen von hochpolymeren Kohlenhydraten mit hydrophoben Wirkflüssigkeiten
|
EP2069343A2
(en)
|
2006-09-15 |
2009-06-17 |
F. Hoffmann-Roche AG |
Process for the preparation of pyrido[2,1-a]isoquinoline derivatives by catalytic asymmetric hydrogenation of an enamine
|
CA2662413C
(en)
|
2006-09-15 |
2015-08-25 |
Stefan Abrecht |
Process for the preparation of pyrido[2,1-a]isoquinoline derivatives comprising optical resolution of an enamine
|
US7956201B2
(en)
|
2006-11-06 |
2011-06-07 |
Hoffman-La Roche Inc. |
Process for the preparation of (S)-4-fluoromethyl-dihydro-furan-2-one
|
CL2007003187A1
(es)
|
2006-11-06 |
2008-03-07 |
Boehringer Ingelheim Int |
Compuestos derivados de bencil-benzonitrilo sustituido con glucopiranosilo y sus sales; procedimiento de preparacion; compuestos intermediarios; proceso para preparar los compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de
|
CA2669043A1
(en)
|
2006-11-09 |
2008-05-15 |
Boehringer Ingelheim International Gmbh |
Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions
|
TW200838536A
(en)
|
2006-11-29 |
2008-10-01 |
Takeda Pharmaceutical |
Polymorphs of succinate salt of 2-[6-(3-amino-piperidin-1-yl)-3-methyl-2,4-dioxo-3,4-dihydro-2H-pyrimidin-1-ylmethy]-4-fluor-benzonitrile and methods of use therefor
|
WO2008070692A2
(en)
|
2006-12-06 |
2008-06-12 |
Smithkline Beecham Corporation |
Bicyclic compounds and use as antidiabetics
|
US7638541B2
(en)
|
2006-12-28 |
2009-12-29 |
Metabolex Inc. |
5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
|
AR064736A1
(es)
|
2007-01-04 |
2009-04-22 |
Prosidion Ltd |
Agonistas de gpcr
|
CL2008000133A1
(es)
|
2007-01-19 |
2008-05-23 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un compuesto derivado de pirazol-o-glucosido combinado con al menos un segundo agente terapeutico; y uso de la composicion para el tratamiento de diabetes mellitus, cataratas, neuropatia, infarto de miocardio, e
|
JP5284968B2
(ja)
|
2007-02-01 |
2013-09-11 |
武田薬品工業株式会社 |
アログリプチンおよびピオグリタゾンを含有する固形製剤
|
WO2008093878A1
(en)
|
2007-02-01 |
2008-08-07 |
Takeda Pharmaceutical Company Limited |
Tablet preparation without causing a tableting trouble
|
AR065698A1
(es)
|
2007-03-13 |
2009-06-24 |
Takeda Pharmaceutical |
Preparacion solida
|
US8093236B2
(en)
|
2007-03-13 |
2012-01-10 |
Takeda Pharmaceuticals Company Limited |
Weekly administration of dipeptidyl peptidase inhibitors
|
JP2010521492A
(ja)
|
2007-03-15 |
2010-06-24 |
ネクティド,インク. |
徐放性ビグアニド組成物、および即時性ジペプチジルペプチダーゼiv阻害剤組成物を含む抗糖尿病合剤
|
JPWO2008114857A1
(ja)
|
2007-03-22 |
2010-07-08 |
杏林製薬株式会社 |
アミノアセチルピロリジンカルボニトリル誘導体の製造方法
|
AU2008233548B2
(en)
*
|
2007-04-03 |
2011-12-01 |
Mitsubishi Tanabe Pharma Corporation |
Combined use of dipeptidyl peptidase IV inhibitor compound and sweetener
|
US9050123B2
(en)
|
2007-04-16 |
2015-06-09 |
Smith & Nephew, Inc. |
Powered surgical system
|
PE20090696A1
(es)
|
2007-04-20 |
2009-06-20 |
Bristol Myers Squibb Co |
Formas cristalinas de saxagliptina y procesos para preparar las mismas
|
EP2144902B1
(en)
|
2007-05-04 |
2012-05-16 |
Bristol-Myers Squibb Company |
[6,6]and [6,7]-bicyclic gpr119 g protein-coupled receptor agonists
|
WO2008144730A2
(en)
|
2007-05-21 |
2008-11-27 |
Phenomix Corporation |
Stable pharmaceutical formulation for a dpp-iv inhibitor
|
EP2178493B2
(en)
|
2007-07-09 |
2015-12-09 |
Symrise AG |
Stable soluble salts of phenylbenzimidazole sulfonic acid at pH 6.0 to below 6.8
|
CA2692758A1
(en)
|
2007-07-12 |
2009-01-15 |
Phenomix Corporation |
A crystalline synthetic intermediate for preparation of a dpp-iv inhibitor and method of purification thereof
|
GEP20125672B
(en)
|
2007-07-19 |
2012-10-25 |
Takeda Pharmaceuticals Co |
) solid composition containing alogliptin and metformin hydrochloride
|
JP2010535781A
(ja)
|
2007-08-03 |
2010-11-25 |
イーライ リリー アンド カンパニー |
肥満に対する処置
|
PE20090597A1
(es)
|
2007-08-16 |
2009-06-06 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un derivado de pirazol-o-glucosido
|
CL2008002427A1
(es)
|
2007-08-16 |
2009-09-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofurano-3-iloxi)bencil]-benceno combinado con 1-[(4-metilquinazolin-2-il)metil]-3-metil-7-(2-butin-1-il)-8-(3-(r)-aminopiperidin-1-il)xantina; y su uso para tratar diabetes mellitus tipo 2.
|
UY31290A1
(es)
|
2007-08-16 |
2009-03-31 |
|
Composicion farmacéutica que comprende un derivado de pirazol-o-glucosido
|
PE20090603A1
(es)
|
2007-08-16 |
2009-06-11 |
Boehringer Ingelheim Int |
Composicion farmaceutica que comprende un inhibidor de sglt2 y un inhibidor de dpp iv
|
CN101784278A
(zh)
|
2007-08-17 |
2010-07-21 |
贝林格尔.英格海姆国际有限公司 |
用于治疗fab-相关的疾病的嘌呤衍生物
|
US8338450B2
(en)
|
2007-09-21 |
2012-12-25 |
Lupin Limited |
Compounds as dipeptidyl peptidase IV (DPP IV) inhibitors
|
PL2209800T3
(pl)
|
2007-11-16 |
2013-12-31 |
Novo Nordisk As |
Stabilne kompozycje farmaceutyczne zawierające liraglutyd i degludec
|
TW200938200A
(en)
|
2007-12-28 |
2009-09-16 |
Dainippon Sumitomo Pharma Co |
Methyl-substituted piperidine derivative
|
CN101234105A
(zh)
|
2008-01-09 |
2008-08-06 |
北京润德康医药技术有限公司 |
一种含有二甲双胍和维格列汀的药用组合物及其制备方法
|
WO2009091663A1
(en)
|
2008-01-14 |
2009-07-23 |
Phenomix Corporation |
Stable pharmaceutical formulation of a dpp-iv inhibitor with metformin
|
US20090186086A1
(en)
|
2008-01-17 |
2009-07-23 |
Par Pharmaceutical, Inc. |
Solid multilayer oral dosage forms
|
TW200936136A
(en)
|
2008-01-28 |
2009-09-01 |
Sanofi Aventis |
Tetrahydroquinoxaline urea derivatives, their preparation and their therapeutic application
|
WO2009099734A1
(en)
|
2008-02-05 |
2009-08-13 |
Merck & Co., Inc. |
Pharmaceutical compositions of a combination of metformin and a dipeptidyl peptidase-iv inhibitor
|
EP2259676A4
(en)
|
2008-03-04 |
2011-03-16 |
Merck Sharp & Dohme |
PHARMACEUTICAL COMPOSITIONS OF A COMBINATION OF METFORMIN AND A DIPEPTIDYL PEPTIDASE-IV INHIBITOR
|
GEP20135844B
(en)
|
2008-03-05 |
2013-06-10 |
Takeda Pharmaceutical |
Heterocyclic compound
|
US8551524B2
(en)
|
2008-03-14 |
2013-10-08 |
Iycus, Llc |
Anti-diabetic combinations
|
MX2010010562A
(es)
|
2008-03-31 |
2010-12-07 |
Metabolex Inc |
Compuestos de oximetilen-arilo y uso de los mismos.
|
PE20140960A1
(es)
|
2008-04-03 |
2014-08-15 |
Boehringer Ingelheim Int |
Formulaciones que comprenden un inhibidor de dpp4
|
WO2009128360A1
(ja)
|
2008-04-18 |
2009-10-22 |
大日本住友製薬株式会社 |
糖尿病治療剤
|
PT2275108E
(pt)
|
2008-05-14 |
2014-09-30 |
Sanwa Kagaku Kenkyusho Co |
Preparação farmacêutica que compreende inibidor de dpp-iv e outro agente terapêutico de diabetes na forma concomitante ou combinada
|
PE20100156A1
(es)
|
2008-06-03 |
2010-02-23 |
Boehringer Ingelheim Int |
Tratamiento de nafld
|
KR20200118243A
(ko)
|
2008-08-06 |
2020-10-14 |
베링거 인겔하임 인터내셔날 게엠베하 |
메트포르민 요법이 부적합한 환자에서의 당뇨병 치료
|
UY32030A
(es)
|
2008-08-06 |
2010-03-26 |
Boehringer Ingelheim Int |
"tratamiento para diabetes en pacientes inapropiados para terapia con metformina"
|
MX370599B
(es)
|
2008-08-15 |
2019-12-18 |
Boehringer Ingelheim Int |
Derivados de purina para su uso en el tratamiento de enfermedades relacionadas con fab.
|
JP2010053576A
(ja)
|
2008-08-27 |
2010-03-11 |
Sumitomo Forestry Co Ltd |
舗装用マット
|
US8513264B2
(en)
|
2008-09-10 |
2013-08-20 |
Boehringer Ingelheim International Gmbh |
Combination therapy for the treatment of diabetes and related conditions
|
UY32177A
(es)
|
2008-10-16 |
2010-05-31 |
Boehringer Ingelheim Int |
Tratamiento de diabetes en pacientes con control glucémico insuficiente a pesar de la terapia con fármaco, oral o no, antidiabético
|
WO2010045656A2
(en)
|
2008-10-17 |
2010-04-22 |
Nectid, Inc. |
Novel sglt2 inhibitor dosage forms
|
AU2009331471B2
(en)
|
2008-12-23 |
2015-09-03 |
Boehringer Ingelheim International Gmbh |
Salt forms of organic compound
|
TW201036975A
(en)
|
2009-01-07 |
2010-10-16 |
Boehringer Ingelheim Int |
Treatment for diabetes in patients with inadequate glycemic control despite metformin therapy
|
TWI466672B
(zh)
|
2009-01-29 |
2015-01-01 |
Boehringer Ingelheim Int |
小兒科病人糖尿病之治療
|
UY32427A
(es)
|
2009-02-13 |
2010-09-30 |
Boheringer Ingelheim Internat Gmbh |
Composicion farmaceutica, forma farmaceutica, procedimiento para su preparacion, metodos de tratamiento y usos de la misma
|
SG173619A1
(en)
|
2009-02-13 |
2011-09-29 |
Boehringer Ingelheim Int |
Pharmaceutical composition comprising a sglt2 inhibitor, a dpp-iv inhibitor and optionally a further antidiabetic agent and uses thereof
|
WO2010092163A2
(en)
*
|
2009-02-13 |
2010-08-19 |
Boehringer Ingelheim International Gmbh |
Antidiabetic medications
|
TW201031661A
(en)
|
2009-02-17 |
2010-09-01 |
Targacept Inc |
Fused benzazepines as neuronal nicotinic acetylcholine receptor ligands
|
EP2408780A2
(en)
|
2009-03-20 |
2012-01-25 |
Pfizer Inc. |
3-oxa-7-azabicycloý3.3.1¨nonanes
|
US8815292B2
(en)
|
2009-04-27 |
2014-08-26 |
Revalesio Corporation |
Compositions and methods for treating insulin resistance and diabetes mellitus
|
WO2010140111A1
(en)
|
2009-06-02 |
2010-12-09 |
Ranbaxy Laboratories Limited |
Pharmaceutical compositions containing a combination of an antihistamine and a decongestant
|
EP2442806A1
(en)
|
2009-06-15 |
2012-04-25 |
Merck Sharp & Dohme Corp. |
Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with pioglitazone
|
MX2012000892A
(es)
|
2009-07-21 |
2012-06-01 |
Keryx Biopharmaceuticals Inc |
Formas de dosificacion de citrato ferrico.
|
US20120219623A1
(en)
|
2009-10-02 |
2012-08-30 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical compositions comprising bi-1356 and metformin
|
US10610489B2
(en)
|
2009-10-02 |
2020-04-07 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, pharmaceutical dosage form, process for their preparation, methods for treating and uses thereof
|
JP5446716B2
(ja)
|
2009-10-21 |
2014-03-19 |
大正製薬株式会社 |
アルギニン及びカルニチン含有錠剤の製造方法
|
KR20240090632A
(ko)
|
2009-11-27 |
2024-06-21 |
베링거 인겔하임 인터내셔날 게엠베하 |
리나글립틴과 같은 dpp-iv 억제제를 사용한 유전자형 검사된 당뇨병 환자의 치료
|
JP2010070576A
(ja)
|
2009-12-28 |
2010-04-02 |
Sato Pharmaceutical Co Ltd |
速溶解性錠剤
|
EP2547339A1
(en)
|
2010-03-18 |
2013-01-23 |
Boehringer Ingelheim International GmbH |
Combination of a gpr119 agonist and the dpp-iv inhibitor linagliptin for use in the treatment of diabetes and related conditions
|
CN102946875A
(zh)
|
2010-05-05 |
2013-02-27 |
贝林格尔.英格海姆国际有限公司 |
组合疗法
|
CA2795105A1
(en)
|
2010-05-05 |
2011-11-10 |
Peter Schneider |
Pharmaceutical formulations comprising pioglitazone and linagliptin
|
JP5707489B2
(ja)
|
2010-06-09 |
2015-04-30 |
ポクセル・エスアーエスPoxelsas |
1型糖尿病の処置
|
EP2585052A4
(en)
|
2010-06-22 |
2014-10-01 |
Twi Pharmaceuticals Inc |
CONTROLLED RELEASE COMPOSITIONS HAVING REDUCED FOOD EFFECT
|
CA2803504C
(en)
|
2010-06-24 |
2022-08-30 |
Boehringer Ingelheim International Gmbh |
A combination for diabetes therapy comprising linagliptin and a long-acting insulin
|
EP2611442B1
(en)
|
2010-09-03 |
2018-07-04 |
Bristol-Myers Squibb Company |
Drug formulations using water soluble antioxidants
|
US9034883B2
(en)
|
2010-11-15 |
2015-05-19 |
Boehringer Ingelheim International Gmbh |
Vasoprotective and cardioprotective antidiabetic therapy
|
WO2012088682A1
(en)
|
2010-12-29 |
2012-07-05 |
Shanghai Fochon Pharmaceutical Co Ltd. |
2-(3-aminopiperidin-1-yl)-[1,2,4]triazolo[1,5-c]pyrimidine-5,7(3h,6h)-dione derivates as dipeptidyl peptidase iv(dpp-iv) inhibitors
|
JP2014504639A
(ja)
|
2011-02-01 |
2014-02-24 |
ブリストル−マイヤーズ スクイブ カンパニー |
アミン化合物を含む医薬製剤
|
UY33937A
(es)
|
2011-03-07 |
2012-09-28 |
Boehringer Ingelheim Int |
Composiciones farmacéuticas que contienen inhibidores de dpp-4 y/o sglt-2 y metformina
|
US8785455B2
(en)
|
2011-05-10 |
2014-07-22 |
Sandoz Ag |
Polymorph of linagliptin benzoate
|
DK2731947T3
(en)
|
2011-07-15 |
2019-04-23 |
Boehringer Ingelheim Int |
SUBSTITUTED DIMERIC QUINAZOLINE DERIVATIVE, PREPARATION AND USE thereof IN PHARMACEUTICAL COMPOSITIONS FOR TREATMENT OF TYPE I AND TYPE II DIABETES
|
US8849828B2
(en)
|
2011-09-30 |
2014-09-30 |
International Business Machines Corporation |
Refinement and calibration mechanism for improving classification of information assets
|
US20130172244A1
(en)
|
2011-12-29 |
2013-07-04 |
Thomas Klein |
Subcutaneous therapeutic use of dpp-4 inhibitor
|
US9139802B2
(en)
|
2012-01-04 |
2015-09-22 |
The Procter & Gamble Company |
Active containing fibrous structures with multiple regions
|
US9555001B2
(en)
|
2012-03-07 |
2017-01-31 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|
US20130303554A1
(en)
|
2012-05-14 |
2013-11-14 |
Boehringer Ingelheim International Gmbh |
Use of a dpp-4 inhibitor in sirs and/or sepsis
|
EP2849755A1
(en)
|
2012-05-14 |
2015-03-25 |
Boehringer Ingelheim International GmbH |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
|
WO2013174767A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference
|
WO2013174768A1
(en)
|
2012-05-24 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
A xanthine derivative as dpp -4 inhibitor for use in the treatment of autoimmune diabetes, particularly lada
|
WO2013174769A1
(en)
|
2012-05-25 |
2013-11-28 |
Boehringer Ingelheim International Gmbh |
Use of keratinocytes as a biologically active substance in the treatment of wounds, such as diabetic wounds, optionally in combination with a dpp-4 inhibitor
|
WO2013179307A2
(en)
|
2012-05-29 |
2013-12-05 |
Mylan Laboratories Limited |
Stabilized pharmaceutical compositions of saxagliptin
|
EP2908806A1
(en)
|
2012-10-09 |
2015-08-26 |
Boehringer Ingelheim International GmbH |
Use of selectively moisture-adjusted tabletting material in the production of mechanically stable tablets which contain at least one hydrate-forming active substance and/or adjuvant relevant to the mechanical stability of the tablets, particularly arginine-containing tablets
|
US20140100292A1
(en)
|
2012-10-09 |
2014-04-10 |
Boehringer Ingelheim International Gmbh |
Use of moisture-conditioned disintegrants or expanding agents in tablet manufacture for the selective adjustment of the mechanical properties, the dissolving kinetics and/or the water loading of the tablets
|
US9050302B2
(en)
|
2013-03-01 |
2015-06-09 |
Jazz Pharmaceuticals Ireland Limited |
Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
|
WO2014140284A1
(en)
|
2013-03-15 |
2014-09-18 |
Boehringer Ingelheim International Gmbh |
Use of linagliptin in cardio- and renoprotective antidiabetic therapy
|
WO2014170383A1
(en)
|
2013-04-18 |
2014-10-23 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition, methods for treating and uses thereof
|
WO2014184376A1
(en)
|
2013-05-17 |
2014-11-20 |
Boehringer Ingelheim International Gmbh |
Combination of a dpp-4 inhibitor and an alpha-glucosidase inhibitor
|
EP3007701A1
(en)
|
2013-06-14 |
2016-04-20 |
Boehringer Ingelheim International GmbH |
Dpp-4 inhibitors for treating diabetes and its complications
|
JP6615109B2
(ja)
|
2014-02-28 |
2019-12-04 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Dpp−4阻害薬の医学的使用
|
WO2016059219A1
(en)
|
2014-10-17 |
2016-04-21 |
Boehringer Ingelheim International Gmbh |
Pharmaceutical composition and uses thereof
|